Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy

Current Drug Targets

Volumn 11, Issue 7, 2010, Pages 865-874

  Rossi, Antonio ^a   Maione, Paolo ^a   Sacco, Paola Claudia ^a   Ambrosio, Rita ^a   Falanga, Marzia ^a   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

NSCLC; Sorafenib; Sunitinib; Tyrosine kinase inhibitors; Vandetanib; VEGF; VEGFR

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AXITINIB; BIBF 1120; BMS 690514; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; DOVITINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; MOTESANIB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB; XL 647; XL 880;

ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVITY; FATIGUE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; RESEARCH; SKIN MANIFESTATION; TREATMENT FAILURE; TUMOR GROWTH; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77953861145     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791320791     Document Type: Article

References (69)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
3. Avastin Treatment Information for Healthcare Professionals -Avastin (bevacizumab). Available at: http://www.avastin.com/ avastin/hcp/index.m [accessed February 11, 2010].
4. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (suppl. 4): iv68-iv70.
5. nd Edition). Chest 2007; 132 (suppl. 3): 277S-89S.
6. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
7. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
8. Keshet E, Ben-Sasson SA. Anticancer drug targets: approaching angiogenesis. J Clin Invest 1999; 104: 1497-501.
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
10. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-14.
11. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-54.
12. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001; 61: 6020-4.
13. Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 2003; 13: 1721-7.
14. Duff SE, Jeziorska M, Rosa DD, et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 2006; 42: 112-7.
15. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24: 2647-53.
16. Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006; 66: 46-51.
17. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000; 5: 24-33.
18. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993; 3: 244-50.
19. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-70.
20. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangio-genesis in wound healing. Am J Pathol 2000; 156; 1499-1504.
21. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
22. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999; 126: 3015-25.
23. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000; 275: 16986-92.
24. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-54.
25. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5: 3364-8.
26. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999; 6: 373-8.
27. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-55.
28. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small cell lung cancer: results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2009; 27: 2523-9.
29. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 5407-15.
30. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25: 4270-7.
31. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009; 27(18S): 807s (abstr. CRA8003).
32. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009; 27(15S): 409s (abstr. 8010).
33. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009; 27(15S): 409s (abstr. 8009).
34. ZEPHYR trial of zactima (vandetanib) vs. placebo -negative. Available at: http://cancergrace.org/lung/2010/01/29/zephyr-trial-negative/ [accessed February 11, 2010].
35. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
36. Minami H, Kawada K, Ebi H, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008; 99: 1492-8.
37. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 4274-80.
38. Schiller J, Lee JW, Hanna NH, Traynor AM, Wakelee H, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Thorac Oncol 2009; 4(suppl. 1): S355-6 (abstr. C1.6).
39. Hanna NH, von Pawel J, Reck M, Scagliotti G. Carboplatin/ paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): Interim analysis (ia) results from a randomized phase III trial (escape). J Thorac Oncol 2008; 3 (suppl.): S268 (abstr. 13).
40. Duran I, Hotté SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 4849-57.
41. Lind JS, Dingemans AC, Groen HJ, Smit EF. A phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15S): 411s (abstr. 8018).
42. Buckstein R, Meyer RM, Seymour L, et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol 2007; 14: 154-61.
43. Britten CD, Kabbinavar F, Randolph Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008; 61: 515-24.
44. Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007; 356: 323-8.
45. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-6.
46. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101: 1543-8.
47. Blumenschein Jr GR, Robert F, Melnyk O, et al. Erlotinib (E) with or without sunitinib (SU) in the treatment of metastatic non-small cell lung cancer (NSCLC): A phase II study. J Thorac Oncol 2008; 3 (suppl. 1): S77-8 (abstr. 212P).
48. Govindan R, Blumenschein G, Groen HJM, et al. Sunitinib plus erlotinib, a novel VEGFR-EGFR co-inhibition treatment strategy in patients (pts) with metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3 (suppl. 1): S79 (abstr. 216P).
49. Crawford J, Burris H, Stephenson J, et al. Safety and phar-macokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer. J Clin Oncol 2007; 25(18S): 616s (abstr. 14057).
50. Blumenschein GR Jr, Reckamp K, Stephenson GJ, et al. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 279-90.
51. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial. Available at: http://www.amgen.com/media/ media_pr_detail.jsp?releaseID=1255738 [accessed February 11, 2010].
52. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-82.
53. von Pawel J, Kaiser R, Eschbach C, et al. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S): 418s (abstr. 7635).
54. Hanna N, Ellis P, Stopfer P, Shapiro D, Gyorffy S. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. J Thorac Oncol 2007; 2 (suppl. 4): S717-8 (abstr. P3-091).
55. Camidge DR, Conkling P, Stephenson JJ, et al. Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15S): 169s (abstr. 3567).
56. LUME-Lung 1: BIBF 1120 plus docetaxel as compared to placebo plus docetaxel in 2nd line non small cell lung cancer. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=6302 97&version=HealthProfessional&protocolsearchid=7337960 [accessed February 11, 2010].
57. LUME Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=6306 48&version=HealthProfessional&protocolsearchid=7337960 [accessed February 11, 2010].
58. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-400.
59. Goss G, Shepherd FA, Laurie S, et al. A phase I and phar-macokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009; 45: 782-8.
60. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmaco-kinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008; 26: 1871-8.
61. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28: 49-55.
62. Bahleda R, Felip E, Herbst RS, et al. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 2008; 26(15S): 128s (abstr. 2564).
63. Bahleda R, Soria J, Harbison C, et al. tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 2009; 27(15S): 431s (abstr. 8098).
64. A comparison between BMS-690514 and erlotinib in patients who were previously treated for NSCLC. Available at: http://www. cancer.gov/search/ViewClinicalTrials.aspx?cdrid=614015&version =HealthProfessional&protocolsearchid=7337983 [accessed February 11, 2010].
65. Bocci G, Man S, Green SK, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004; 64: 6616-25.
66. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009; 15: 3600-9.
67. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 193-201.
68. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-202.
69. Goodwin RA, Seymour L, Ding K, et al. Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer. J Clin Oncol 2009; 27(15S): 152s (abstr. 3527).